Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | STK4 | Q13043 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072777 | 0.94 | AKR1C3 (0.35) | MAPTIDO1ALDH1A1CREBBPSTK4 | |
| SCHEMBL6072013 | 0.92 | IDO1 (0.40) | MAPTIDO1ALDH1A1POLBKMT2A | |
| SCHEMBL6071890 | 0.90 | POLB (0.36) | MAPTTDP1ALDH1A1L3MBTL1POLB | |
| SCHEMBL6071599 | 0.90 | TDP1 (0.32) | TDP1IRAK4 | |
| SCHEMBL6071949 | 0.90 | HDAC1 (0.38) | MAPTALDH1A1L3MBTL1CREBBPPOLB | |
| SCHEMBL6072104 | 0.89 | FFAR4 (0.33) | IDO1TDP1IRAK4 | |
| Hydrochloric Acid SCHEMBL6072515 | 0.89 | TDP1 (0.32) | TDP1IRAK4 | |
| SCHEMBL6071796 | 0.89 | ALDH1A1 (0.35) | MAPTTDP1ALDH1A1L3MBTL1POLB | |
| SCHEMBL6072201 | 0.88 | TDP1 (0.39) | MAPTIDO1TDP1ALDH1A1STK4 | |
| SCHEMBL6072481 | 0.87 | IDO1 (0.33) | MAPTIDO1TDP1ALDH1A1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2000021936-A1 | URACIL HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | MAPT 4861/4885ALOX15 2448/4885IDO1 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.